Corcept Therapeutics (CORT) Revenue (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Revenue data on file, last reported at $164.9 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 4.89% year-over-year to $164.9 million; the trailing twelve-month figure through Mar 2026 stood at $769.1 million (up 12.2% YoY), and the FY2025 full-year result was $761.4 million, up 12.79% from the prior year.
• Revenue retreated to $164.9 million in Q1 2026, from $202.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $207.6 million in Q3 2025 to a low of $93.7 million in Q1 2022.
• A 5-year average of $146.2 million and a median of $146.8 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue climbed 4.28% in 2022 and jumped 47.69% in 2024, its largest moves.
• Tracing CORT's Revenue over 5 years: stood at $103.1 million in 2022, then jumped by 31.39% to $135.4 million in 2023, then soared by 34.33% to $181.9 million in 2024, then rose by 11.12% to $202.1 million in 2025, then slipped by 18.42% to $164.9 million in 2026.
• Business Quant data shows CORT's Revenue at $164.9 million in Q1 2026, $202.1 million in Q4 2025, and $207.6 million in Q3 2025.